IP Library › Granted Patent US 12,195,533
Granted Patent B2
US 12,195,533 · App. 16/520,293 · Granted Jan 14, 2025

Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same

Inventors: Brendan P. Eckelman (Encinitas, CA); Michael D. Kaplan (San Diego, CA); Katelyn M. Willis (Encinitas, CA); Quinn Deveraux (La Jolla, CA); Kyle S. Jones (San Marcos, CA); Rajay A. Pandit (San Diego, CA); John C. Timmer (La Jolla, CA)
Assignee: Inhibrx Biosciences, Inc.
C07K16/2809C07K16/2818C07K16/2827C07K16/2878C07K2317/24C07K2317/31C07K2317/56C07K2317/624
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,533
App. No.
16/520,293
Granted
Jan 14, 2025
Kind
B2
Abstract

The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Claims (63)

1. A multispecific polypeptide construct, the multispecific polypeptide construct comprising a first component comprising an immunoglobulin Fc region and a second component comprising a CD3-binding region, wherein:

the CD3-binding region is an anti-CD3 disulfide-stabilized Fv antibody fragment (anti-CD3 dsFv) comprising a variable heavy chain region (VH) and a variable light chain region (VL);

the Fc is a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, wherein the VH and VL of the anti-CD3 dsFv are linked to opposite polypeptides of the heterodimeric Fc;

the first and second components are coupled by a first polypeptide linker, wherein the first linker is 3-18 amino acids in length, wherein the Fc region is positioned amino-terminally relative to the CD3-binding region;

one or both of the first and second components comprises at least one antigen binding domain that binds a tumor associated antigen (TAA), wherein each of the at least one antigen binding domain(s) is a camelid V H H or a humanized camelid V H H, wherein the at least one antigen binding domain(s) is coupled to the construct by a second polypeptide linker that is 2-6 amino acids in length; and

one or both of the first and second components comprises at least one co-stimulatory receptor binding region (CRBR) that binds a co-stimulatory receptor, wherein each of the at least one CRBR(s) is a camelid V H H or a humanized camelid V H H, wherein the at least one CRBR(s) is coupled to the construct by a third polypeptide linker that is 2-6 amino acids in length;

wherein each linker is independently composed of at least 50% glycine residues; and

wherein the CD3-binding region is not able to bind cell surface CD3 as determined by flow cytometry, unless at least one of the antigen binding domain is bound to its TAA.

2. The multispecific polypeptide construct of claim 1 , wherein the first component comprises the at least one antigen binding domain that binds a TAA, wherein the at least one antigen binding domain comprises a first antigen binding domain and a second antigen binding domain, wherein each of the antigen binding domains binds a TAA.

3. The multispecific polypeptide construct of claim 1 , wherein the at least one antigen binding domain comprises a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain is positioned amino-terminally relative to the Fc region of the multispecific polypeptide construct and the second antigen binding domain is positioned carboxy-terminally relative to the CD3-binding region of the multispecific polypeptide construct.

4. The multispecific polypeptide construct of claim 1 , wherein the at least one CRBR is positioned carboxy-terminally relative to the CD3-binding region of the multispecific polypeptide construct.

5. A multispecific polypeptide construct, comprising in order from N-terminus to C-terminus:

(a) a co-stimulatory receptor binding region (CRBR) that binds a co-stimulatory receptor and/or an antigen binding domain that binds a tumor associated antigen (TAA);

(b) an immunoglobulin Fc region that is a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, wherein the CRBR and/or antigen binding domain of (a) are coupled to the immunoglobulin Fc region by a polypeptide linker that is 2-6 amino acids in length;

(c) a polypeptide linker that is 3-18 amino acids in length;

(d) a CD3-binding region that is an anti-CD3 disulfide-stabilized Fv antibody fragment (anti-CD3 dsFv) comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein the VH and VL of the anti-CD3 dsFv are linked to opposite polypeptides of the heterodimeric Fc; and

(e) a CRBR that binds a co-stimulatory receptor and/or an antigen binding domain that binds to a TAA, wherein the CRBR and/or antigen binding domain are coupled to the CD3-binding region by a polypeptide linker that is 2-6 amino acids in length,

wherein:

each linker is independently composed of at least 50% glycine residues;

wherein the multispecific polypeptide construct comprises (i) at least one CRBR, and the at least one CRBR is a camelid V H H or a humanized camelid V H H and (ii) at least one antigen binding domain that binds a TAA, and the at least one antigen binding domain is a camelid V H H or a humanized camelid V H H; and

wherein the CD3-binding region is not able to bind cell surface CD3 as determined by flow cytometry, unless at least one of the antigen binding domain is bound to its TAA.

6. A multispecific polypeptide construct, wherein the multispecific polypeptide construct comprises in order, from N-terminus to C-terminus:

(1) (a) an immunoglobulin Fc region that is a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide;

(b) a polypeptide linker that is 3-18 amino acids in length;

(c) a CD3-binding region that is an anti-CD3 disulfide-stabilized Fv antibody fragment (anti-CD3 dsFv) comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein the VH and VL of the anti-CD3 dsFv are linked to opposite polypeptides of the heterodimeric Fc; and

(d) an antigen binding domain that binds a tumor associated antigen (TAA) and a co-stimulatory receptor binding region (CRBR) that binds a co-stimulatory receptor, wherein the antigen binding domain and CRBR are coupled to the CD3-binding region by a polypeptide linker that is 2-6 amino acids in length; or

(2) (a) an antigen binding domain that binds a TAA and a CRBR that binds a co-stimulatory receptor;

(b) an immunoglobulin Fc region that is a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, wherein the antigen binding domain and CRBR of (2)(a) are coupled to the immunoglobulin Fc region by a polypeptide linker that is 2-6 amino acids in length;

(c) a polypeptide linker that is 3-18 amino acids in length; and

(d) a CD3-binding region that is an anti-CD3 disulfide-stabilized Fv antibody fragment (anti-CD3 dsFv) comprising a variable heavy chain region (VH) and a variable light chain region (VL), wherein the VH and VL of the anti-CD3 dsFv are linked to opposite polypeptides of the heterodimeric Fc; wherein

each linker is independently composed of at least 50% glycine residues wherein:

(i) the CD3-binding region is not able to bind cell surface CD3 as determined by flow cytometry, unless the antigen binding domain is bound to its TAA; and

(ii) each of the CRBR and the antigen binding domain is a camelid V H H or a humanized camelid V H H.

7. The multispecific polypeptide construct of claim 1 , wherein one or both Fc polypeptides of the heterodimeric Fc region comprises (a) a knob-into-hole modification or (b) a charge mutation to increase electrostatic complementarity of the polypeptides.

8. The multispecific polypeptide construct of claim 1 , wherein the first polypeptide linker is a cleavable polypeptide linker.

9. The multispecific polypeptide construct of claim 1 , wherein the first polypeptide linker is a non-cleavable polypeptide linker.

10. The multispecific polypeptide construct of claim 9 , wherein the non-cleavable polypeptide linker comprises (GGS)n, wherein n is 1 to 10; (GGGGS)n (SEQ ID NO: 173), wherein n is 1 to 10; or (GGGGGS)n (SEQ ID NO:172), wherein n is 1 to 4.

11. The multispecific polypeptide construct of claim 1 , wherein the at least one antigen binding domain comprises:

a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain and the second antigen binding domain bind to the same TAA;

a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain and the second antigen binding domain bind different epitopes of the same TAA;

a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain and the second antigen binding domain bind the same epitope of the same TAA; or

a first antigen binding domain and a second antigen binding domain wherein the first antigen binding domain and the second antigen binding domain bind different TAAs.

12. The multispecific polypeptide construct of claim 1 , wherein the at least one CRBR binds a co-stimulatory receptor selected from the group consisting of: 41BB (CD137), OX40 (CD134), CD27, glucocorticoid-induced TNFR-related protein (GITR), CD28, ICOS, CD40, B-cell activating factor receptor (BAFF-R), B-cell maturation antigen (BCMA), Transmembrane activator and CAML interactor (TACI), and NKG2D.

13. The multispecific polypeptide construct of claim 1 , wherein the at least one CRBR binds to 41BB (CD137).

14. The multispecific polypeptide construct of claim 1 , wherein the anti-CD3 dsFv comprises:

a VH CDR1 comprising the amino acid sequence TYAMN (SEQ ID NO:16); a VH CDR2 comprising the amino acid sequence RIRSKYNNYATYYADSVKD (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 comprising the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 21);

a VH CDR1 comprising the amino acid sequence GFTFNTYAMN (SEQ ID NO: 312); a VH CDR2 comprising the amino acid sequence RIRSKYNNYATY (SEQ ID NO: 318); a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 comprising the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 21); or

a VH CDR1 comprising the amino acid sequence GFTFNTYAMN (SEQ ID NO: 312); a VH CDR2 comprising the amino acid sequence RIRSKYNNYATY (SEQ ID NO: 318); a VH CDR3 comprising the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 comprising the amino acid sequence GSSTGAVTTSNYAN (SEQ ID NO: 319); a VL CDR2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 320); and a VL CDR3 comprising the amino acid sequence ALWYSNHWV (SEQ ID NO: 315).

15. The multispecific polypeptide construct of claim 1 , wherein the multispecific polypeptide construct is conjugated to an agent selected from the group consisting of: a therapeutic agent, an antineoplastic agent, a toxin or fragment thereof, a detectable moiety, and a diagnostic agent.

16. A pharmaceutical composition comprising the multispecific polypeptide construct of claim 1 and a pharmaceutically acceptable carrier.

17. The multispecific polypeptide construct of claim 1 , wherein the multispecific polypeptide construct comprises only one CRBR.

18. The multispecific polypeptide construct of claim 4 , wherein the multispecific polypeptide construct comprises only one CRBR.

19. The multispecific polypeptide construct of claim 18 , wherein the CRBR binds to 41BB.

20. The multispecific polypeptide construct of claim 9 , wherein the non-cleavable polypeptide linker comprises the amino acid sequence set forth in any one of SEQ ID NO:10, SEQ ID NO:119, and SEQ ID NO:170.

21. The multispecific polypeptide construct of claim 1 , wherein the anti-CD3 dsFv comprises:

a VH having the amino acid sequence of any of SEQ ID NOS: 44, 49-62, 290, and 311; and

a VL having the amino acid sequence of any of SEQ ID NOS: 64, 72, 74, 76, 78-81, 241 and 289.

22. The multispecific polypeptide construct of claim 1 , wherein the anti-CD3 dsFv comprises a VH having the amino acid sequence of SEQ ID NO: 44; and a VL having the amino acid sequence of SEQ ID NO: 72.

23. The multispecific polypeptide construct of claim 1 , wherein the anti-CD3 dsFv comprises a VH CDR1 sequence that includes at least the amino acid sequence GFTFNTYAMN (SEQ ID NO: 312); a VH CDR2 sequence that includes at least the amino acid sequence RIRSKYNNYATY (SEQ ID NO: 313); a VH CDR3 sequence that includes at least the amino acid sequence HGNFGNSYVSWFAY (SEQ ID NO: 18), a VL CDR1 sequence that includes at least the amino acid sequence GSSTGAVTTSNYAN (SEQ ID NO: 319); a VL CDR2 sequence that includes at least the amino acid sequence GTNKRAP (SEQ ID NO: 320); and a VL CDR3 sequence that includes at least the amino acid sequence ALWYSNHWV (SEQ ID NO: 315).

24. The multispecific polypeptide construct of claim 1 , wherein the second component comprises the at least one co-stimulatory receptor binding region (CRBR).

25. The multispecific polypeptide construct of claim 2 , wherein the second component comprises the at least one co-stimulatory receptor binding region (CRBR).

26. The multispecific polypeptide construct of claim 23 , wherein the anti-CD3 dsFv comprises a VH having a sequence that exhibits at least 90% sequence identity to SEQ ID NO: 44; and a VL having a sequence that exhibits at least 90% sequence identity to SEQ ID NO: 72.

27. The multispecific polypeptide construct of claim 2 , wherein the at least one CRBR is positioned carboxy-terminally relative to the CD3-binding region of the multispecific polypeptide construct.

Assignments (5)
SECURITY INTEREST Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2019
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN; JONES, KYLE S.; PANDIT, RAJAY A.; TIMMER, JOHN C.
To: INHIBRX, INC.
Reel/Frame 050895/0085 →
Continuity (4)
Provisional Application 62832268 · Apr 10, 2019
Provisional Application 62744641 · Oct 11, 2018
Provisional Application 62702888 · Jul 24, 2018
Related Publication 20200048350A1 · Feb 13, 2020
References Cited (226)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 5258498A · Huston et al. · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5525491A · Huston et al. · 1996 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 6132992A · Ledbetter et al. · 2000 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7959925B2 · Weinberg et al. · 2011 [cited by applicant]
US 8044178B2 · Boghaert et al. · 2011 [cited by applicant]
US 9006399B2 · Liu et al. · 2015 [cited by applicant]
US 9346884B2 · Beste et al. · 2016 [cited by applicant]
US 9605084B2 · Moore et al. · 2017 [cited by applicant]
US 9644016B2 · Stagliano et al. · 2017 [cited by applicant]
US 9650446B2 · Moore et al. · 2017 [cited by applicant]
US 9701759B2 · Desjarlais et al. · 2017 [cited by applicant]
US 10010626B2 · Chang · 2018 [cited by examiner]
US 10066015B2 · Zhukovsky · 2018 [cited by examiner]
US 10087250B2 · Bruenker et al. · 2018 [cited by applicant]
US 10093742B2 · Timmer et al. · 2018 [cited by applicant]
US 10131710B2 · Moore et al. · 2018 [cited by applicant]
US 10858417B2 · Moore · 2020 [cited by examiner]
US 11866507B2 · Eckelman et al. · 2024 [cited by applicant]
US 20050123546A1 · Umana et al. · 2005 [cited by applicant]
US 20110097339A1 · Holmes et al. · 2011 [cited by applicant]
US 20110274685A1 · Keler et al. · 2011 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20120237498A1 · Ahrens et al. · 2012 [cited by applicant]
US 20130183321A1 · Smith et al. · 2013 [cited by applicant]
US 20130273054A1 · Bossenmaier et al. · 2013 [cited by applicant]
US 20140072581A1 · Dixit et al. · 2014 [cited by applicant]
US 20140140989A1 · Eckelman et al. · 2014 [cited by applicant]
US 20140154253A1 · Ng et al. · 2014 [cited by applicant]
US 20140288275A1 · Moore et al. · 2014 [cited by applicant]
US 20140294823A1 · Moore et al. · 2014 [cited by applicant]
US 20140348841A1 · Schebye et al. · 2014 [cited by applicant]
US 20140363426A1 · Moore et al. · 2014 [cited by applicant]
US 20150064204A1 · Beers et al. · 2015 [cited by applicant]
US 20150079088A1 · Lowman et al. · 2015 [cited by applicant]
US 20150087810A1 · Moore et al. · 2015 [cited by applicant]
US 20150239991A1 · Blein et al. · 2015 [cited by applicant]
US 20150307617A1 · Du et al. · 2015 [cited by applicant]
US 20150307628A1 · Kim et al. · 2015 [cited by applicant]
US 20160039942A1 · Cobbold et al. · 2016 [cited by applicant]
US 20160122425A1 · Daugherty et al. · 2016 [cited by applicant]
US 20160194399A1 · Irving et al. · 2016 [cited by applicant]
US 20160289324A1 · Moore et al. · 2016 [cited by applicant]
US 20170022284A1 · Timmer et al. · 2017 [cited by applicant]
US 20170037130A1 · Raum et al. · 2017 [cited by applicant]
US 20170081397A1 · Stagliano et al. · 2017 [cited by applicant]
US 20170114141A1 · Amann et al. · 2017 [cited by applicant]
US 20170137517A1 · Bowman · 2017 [cited by applicant]
US 20170198050A1 · Eckelman et al. · 2017 [cited by applicant]
US 20170198051A1 · Eckelman et al. · 2017 [cited by applicant]
US 20170204139A1 · Moore et al. · 2017 [cited by applicant]
US 20170209492A1 · June · 2017 [cited by applicant]
US 20170226215A1 · Gray et al. · 2017 [cited by applicant]
US 20170320958A1 · Timmer et al. · 2017 [cited by applicant]
US 20180011883A1 · Goldbrenner et al. · 2018 [cited by applicant]
US 20180016354A1 · Wozniak-Knopp et al. · 2018 [cited by applicant]
US 20180230225A1 · Fan · 2018 [cited by examiner]
US 20190010242A1 · Eckelman et al. · 2019 [cited by applicant]
US 20190100594A1 · Timmer et al. · 2019 [cited by applicant]
US 20190218515A1 · Ballesteros Nobell et al. · 2019 [cited by applicant]
US 20190330366A1 · Eckelman et al. · 2019 [cited by applicant]
US 20200190193A1 · Pandit et al. · 2020 [cited by applicant]
US 20210340273A1 · Timmer · 2021 [cited by examiner]
US 20210380679A1 · Eckelman · 2021 [cited by examiner]
US 20230124851A1 · Eckelman et al. · 2023 [cited by applicant]
US 20230295336A1 · Eckelman et al. · 2023 [cited by applicant]
US 20230348600A1 · Timmer et al. · 2023 [cited by applicant]
US 20240101704A1 · Eckelman et al. · 2024 [cited by applicant]
CN 108084265 · 2018 [cited by applicant]
EP 1378520 · 2004 [cited by applicant]
EP 1736484 · 2006 [cited by applicant]
EP 3502140 · 2019 [cited by applicant]
JP 2010535032 · 2010 [cited by applicant]
JP 2013538204 · 2013 [cited by applicant]
WO WO1998050431 · 1998 [cited by applicant]
WO WO2000024884 · 2000 [cited by applicant]
WO WO2005035584 · 2005 [cited by applicant]
WO WO2005063816 · 2005 [cited by applicant]
WO WO2005100402 · 2005 [cited by applicant]
WO WO2006029879 · 2006 [cited by applicant]
WO WO2009018386 · 2009 [cited by applicant]
WO WO2009089004 · 2009 [cited by applicant]
WO WO2009124931 · 2009 [cited by applicant]
WO WO2010009391 · 2010 [cited by applicant]
WO WO2010037836 · 2010 [cited by applicant]
WO WO2010151792 · 2010 [cited by applicant]
WO WO2011028683 · 2011 [cited by applicant]
WO WO2011143545 · 2011 [cited by applicant]
WO WO2012025525 · 2012 [cited by applicant]
WO WO2012058768 · 2012 [cited by applicant]
WO WO2012162067 · 2012 [cited by applicant]
WO WO2013041687 · 2013 [cited by applicant]
WO WO2013101909 · 2013 [cited by applicant]
WO WO2013128194 · 2013 [cited by applicant]
WO WO2014067011 · 2014 [cited by applicant]
WO WO2014099997 · 2014 [cited by applicant]
WO WO2014125273 · 2014 [cited by applicant]
WO WO2014145806 · 2014 [cited by applicant]
WO WO2015026894 · 2015 [cited by applicant]
WO WO2015168469 · 2015 [cited by applicant]
WO WO2015197598 · 2015 [cited by applicant]
WO WO2015197789 · 2015 [cited by applicant]
WO WO2016020309 · 2016 [cited by applicant]
WO WO2016033225 · 2016 [cited by applicant]
WO WO2016034666 · 2016 [cited by applicant]
WO WO2016046778 · 2016 [cited by applicant]
WO WO2016055593 · 2016 [cited by applicant]
WO WO2016086189 · 2016 [cited by applicant]
WO WO2016087416 · 2016 [cited by applicant]
WO WO2016097408 · 2016 [cited by applicant]
WO WO2016105450 · 2016 [cited by applicant]
WO WO2016138038 · 2016 [cited by applicant]
WO WO2016177762 · 2016 [cited by applicant]
WO WO2016179517 · 2016 [cited by applicant]
WO WO2016180982 · 2016 [cited by applicant]
WO WO2016192613 · 2016 [cited by applicant]
WO WO2017015623 · 2017 [cited by applicant]
WO WO2017021349 · 2017 [cited by applicant]
WO WO2017030926 · 2017 [cited by applicant]
WO WO2017055398 · 2017 [cited by applicant]
WO WO2017060144 · 2017 [cited by applicant]
WO WO2017068186 · 2017 [cited by applicant]
WO WO2017123650 · 2017 [cited by applicant]
WO WO2017123673 · 2017 [cited by applicant]
WO WO2017134140 · 2017 [cited by applicant]
WO WO2017134440 · 2017 [cited by applicant]
WO WO2017167672 · 2017 [cited by applicant]
WO WO2017172981 · 2017 [cited by applicant]
WO WO2017182672 · 2017 [cited by applicant]
WO WO2018014260 · 2018 [cited by applicant]
WO WO2018027025 · 2018 [cited by applicant]
WO WO2018068201 · 2018 [cited by applicant]
WO WO2018068695 · 2018 [cited by applicant]
WO WO2018127473 · 2018 [cited by applicant]
WO WO2018167486 · 2018 [cited by applicant]
WO WO2018185045 · 2018 [cited by applicant]
WO WO2018191438 · 2018 [cited by applicant]
WO WO2019200022 · 2019 [cited by applicant]
WO WO2019201866 · 2019 [cited by applicant]
WO WO2020023553 · 2020 [cited by applicant]
WO WO2020076970 · 2020 [cited by applicant]
WO WO2020076977 · 2020 [cited by applicant]
WO WO2020076992 · 2020 [cited by applicant]
WO WO2020077257 · 2020 [cited by applicant]
WO WO2021155071 · 2021 [cited by applicant]
Driessens et al., Immunological Reviews (2009), vol. 229: 126-144. (Year: 2009). [cited by examiner]
Malia et al., Proteins, 2016; 84:427-434. (Year: 2016). [cited by examiner]
Barthelemy et al., Journal of Biological Chemistry, 2008, 283:3639-3654. (Year: 2008). [cited by examiner]
Beiboer et al., Journal of Molecular Biology, 2000, 296:833-849. (Year: 2000). [cited by examiner]
Choi et al., 2011, Molecular BioSystems, 2011, 7:3327-334. (Year: 2011). [cited by examiner]
De Genst et al., Developmental and Comparative Immunology, 2006, 30:187-98. (Year: 2006). [cited by examiner]
Griffiths et al., The EMBO Journal, 1993, 12:725-734. (Year: 1993). [cited by examiner]
Klimka et al., British Journal of Cancer, 2000, 83:252-260. (Year: 2000). [cited by examiner]
Ward et al, Nature, 1989, 341:544-546. (Year: 1989). [cited by examiner]
Kumar et al., “Molecular cloning and expression of the Fabs of human autoantibodies in [cited by applicant]
Smith-Gill et al., “Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens,” J. Immunol. (1987) 139(12):4135-44. [cited by applicant]
Song et al., “Light chain of natural antibody plays a dominant role in protein antigen binding,” Biochem. Biophys. Res. Comm. (2000) 268(2):390-94. [cited by applicant]
Taylor et al., “Nanocell targeting using engineered bispecific antibodies,” Mabs (2015) 7(1):53-65. [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Huet et al., “Multivalent nanobodies targeting death receptor 5 elicit superior tumor killing through efficient caspase induction,” MABS (2014) 6(6):1560-70. [cited by applicant]
Husain et al., “Expanding the boundaries of biotherapeutics with bispecific antibodies,” Biodrugs (2018) 32(5):441-64. [cited by applicant]
Cheng et al., “Construction and expression of a reshaped VH domain against human CD28 molecules,” Preparative Biochemistry and Biotechnology (2002) 32(3):239-251. [cited by applicant]
Ohannesian et al., “Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells,” Cancer Res. (1995) 55(10): 2191-2199. [cited by applicant]
Henry et al., “Stability-Diversity tradeoffs impose fundamental constraints on selection of synthetic human VH/VL single-domain antibodies from in vitro display libraries,” Frontiers in Immunology (2017) 8:1-15. [cited by applicant]
Kim et al., “Mutational approaches to improve the biophysical properties of human single-domain antibodies,” Biochimica et Biophysica Acta (2014) 1844:1983-2001. [cited by applicant]
Alegre et al., “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a ”humanized“ OKT3 monoclonal antibody,” J Immunol (1992) 148(11):3461-3468. [cited by applicant]
Bacac et al., “CD20 Tcb (RG6026), a Novel “2:1” T Cell Bispecific Antibody for the Treatment of B Cell Malignancies,” Blood (2016) 128:1836. [cited by applicant]
Baldrick, “Pharmaceutical Excipient Development: The Need for Preclinical Guidance,” Regul Toxicol Pharm (2000) 32(2):210-218. [cited by applicant]
Beliveau et al., “Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides,” FEBS J (2009) 276(8):2213-2226. [cited by applicant]
Brinkmann et al., “The making of bispecific antibodies,” MABS (2017) 9(2):182-212. [cited by applicant]
Bruggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” J Exp Med (1987) 166(5):1351-1361. [cited by applicant]
Carter et al., “Bispecific human lgG by design,” J Immunol Methods (2001) 248(1-2):7-15. [cited by applicant]
Charman, “Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts,” J Pharm Sci (2000) 89(8):967-978. [cited by applicant]
Chen et al., “Fusion protein linkers: property, design and functionality,” Adv Drug Deliv Rev (2013) 65(10):1357-1369. [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci USA (1998) 95(2):652-656. [cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood (2004) 103:2738-2743. [cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood (2003) 101(3):1045-1052. [cited by applicant]
Dall'Acqua et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)*,” J Biol Chem (2006) 281(33):23514-23524. [cited by applicant]
Davies et al., “Antibody-Antigen Complexes,” Annu Rev Biochem (1990) 59:439-473. [cited by applicant]
Davis et al., “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies,” Protein Eng De… [cited by applicant]
Deisenhofer, “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from [cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods (1997) 202(2):163-171. [cited by applicant]
Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent lgG,” J Biol Chem (2010) 285(25):19637-19646. [cited by applicant]
Ha et al., “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins,” Front Immunol (2016) 7:394. [cited by applicant]
Harwood et al., “ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy,” Oncoimmunology (2018) 7(1):e1377874. [cited by applicant]
Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci USA (1986) 83(18):7059-7063. [cited by applicant]
Hellstrom et al., “Strong antitumor activities of lgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci USA (1985) 82(5):1499-1502. [cited by applicant]
Hernandez-Hoyos et al., “MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer,” Mol Cancer Ther (2016) 15(9):2155-2165. [cited by applicant]
Idusogie et al., “Engineered antibodies with increased activity to recruit complement,” J Immunol (2001) 166(4):2571-2575. [cited by applicant]
Jendeberg et al., “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A,” J Immnuol Methods (1997) 201(1):25-34. [cited by applicant]
Kaneko et al., “Optimizing Therapeutic Antibody Function,” Biodrugs (2011) 25(1):1-11. [cited by applicant]
La Rocca et al., “Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera,” British Journal of Cancer (2004) 90:1414-1421. [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” Proc Natl Acad Sci USA (2006) 103(11):4005-4010. [cited by applicant]
Leaver-Fay et al., “Computationally Designed Bispecific Antibodies using Negative State Repertoires,” Structure (2016) 24(4):641-651. [cited by applicant]
Malmqvist, “Biospecific interaction analysis using biosensor technology,” Nature (1993) 361:186-187. [cited by applicant]
Marasco et al., “Design, intracellular expression, and activity of a human antihuman immunodeficiency virus type 1 gp120 single-chain antibody,” Proc Natl Acad Sci USA (1993) 90(16):7889-7893. [cited by applicant]
Merchant et al., “An efficient route to human bispecific lgG,” Nat Biotechnol (1998) 16(7):677-681. [cited by applicant]
Miller, “Protein-protein recognition and the association of immunoglobulin constant domains,” JMB (1990) 216(4):965-973. [cited by applicant]
Moore et al., “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” MAbs (2011) 3(6):546-557. [cited by applicant]
Moore et al., “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions,” MAbs (2010) 2(2):181-189. [cited by applicant]
Natsume et al., “Engineered Antibodies of lgG1/lgG3 Mixed Isotype with Enhanced Cytotoxic Activities,” Cancer Res (2008) 68(10):3863-3872. [cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human lgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol (2006) 18(12):1759-1769. [cited by applicant]
Powell et al., “Compendium of excipients for parenteral formulations,” PDA J Pharm Sci Technol (1998) 52(5):238-311. [cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein engineering (1996) 9(7):617-621. [cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*,” JBC (2001) 276(9):6591-6604. [cited by applicant]
Stavenhagen et al., “Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization,” Adv Enzyme Regul (2008) 48:152-164. [cited by applicant]
Stavenhagen et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors,” Cancer Res (2007) 67(18… [cited by applicant]
Von Kreudenstein et al., “Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design,” MAbs (2013) 5(5):646-654. [cited by applicant]
Wang, “Lyophilization and development of solid protein pharmaceuticals,” Int J Pharm (2000) 203(1-2):1-60. [cited by applicant]
Xing et al., “BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells,” Transl Oncol (2017) 10(5):780-785. [cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity,” Nat Biotechnol (2010) 28(2):157-159. [cited by applicant]
U.S. Appl. No. 17/283,902, filed Apr. 8, 2021, by Eckelman et al. (Copy not provided). Copy not submitted herewith pursuant to the waiver of 37 C.F. R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Asano et al. “Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody.” [cited by applicant]
Kuo et al., “Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells,” Protein Eng Des Sel. (2012) 25(10): 561-9. [cited by applicant]
Stavenhagen et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcy Receptors,” Cancer Res (2007) 67(18… [cited by applicant]
Weidle et al. “The intriguing options of multispecific antibody formats for treatment of cancer.” [cited by applicant]
Schmiedel e tal. “Expression of a bispecific dsFv-dsFv' antibody fragment in [cited by applicant]
Ma et al., “Targeting immunotherapy for bladder cancer using anti-CD3x B7-H3 bispecific antibody,” Cancer Med (2018) 7(10):5167-5177. [cited by applicant]
Maeda et al., “Engineering of functional chimeric protein G-Vargula luciferase,” Anal Biochem. (1997) 249(2):147-52. [cited by applicant]
Miyazaki, “Studies on Alpaca VHH antibodies for industrial applications,” Kagoshima University Repository, Jun. 1, 2015, 102 pages. https://ir.kagoshima-u.ac.jp/records/9025 (Machine translation provided). [cited by applicant]
Zhang et al., “Amplification Ex Vivo and Cytocidal Activity of Leukemia Tumor-Associated Antigen-Specific Cytotoic T Lympohcytes,” Chinese Journal of Experimental Hematology, (2015) 23(3); 814-820; (Article in Chinese; … [cited by applicant]